Last reviewed 2026-06-02 · How we verify

MOQUIZONE

Phase 2 active Small molecule ✓ Verified Jun 2026

MOQUIZONE is a moquizone drug. It is currently in Phase 2 development.

MOQUIZONE works by binding to a specific target, altering its activity to produce therapeutic effects.

MOQUIZONE is a small molecule modality. It is also known by the synonyms MOQUIZONA.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MOQUIZONE
Drug class	moquizone
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of MOQUIZONE like a key that fits into a lock. The lock is a specific protein in the body, and when the key (MOQUIZONE) binds to it, it changes the way the protein works. This change can help to treat a particular disease or condition.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MOQUIZONE CI brief — competitive landscape report
MOQUIZONE updates RSS · CI watch RSS

Frequently asked questions about MOQUIZONE

What is MOQUIZONE?

MOQUIZONE is a moquizone drug.

How does MOQUIZONE work?

MOQUIZONE works by binding to a specific target, altering its activity to produce therapeutic effects.

What drug class is MOQUIZONE in?

MOQUIZONE belongs to the moquizone class. See all moquizone drugs at /class/moquizone.

What development phase is MOQUIZONE in?

MOQUIZONE is in Phase 2.

Drug class: All moquizone drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing